M&A: Page 14


  • Image attribution tooltip
    Fotolia
    Image attribution tooltip

    Hillrom steps back from $375M BardyDx deal on reimbursement setback

    The hospital products maker said a Medicare contractor's unexpected drop in payment rates for BardyDx's cardiac monitoring technology meant closing conditions for the transaction had not been satisfied.

    By March 1, 2021
  • NuVasive buys Simplify Medical in play for $2.6B cervical spine market

    The $150 million acquisition will add to the pandemic-related challenges for NuVasive in 2021, with investments to train surgeons and run clinical trials offsetting the low anticipated sales this year.

    By Feb. 26, 2021
  • Image attribution tooltip
    Adobe Stock
    Image attribution tooltip

    Axonics adds incontinence device to portfolio in $200M Contura takeover

    The targeted prescribers of Contura's urethral bulking agent are the same physicians who use Axonics' implantable sacral neuromodulation to treat urinary disorders. Analysts said the business logic seems sound.

    By Feb. 26, 2021
  • Image attribution tooltip
    Dollar Photo Club
    Image attribution tooltip

    Exact Sciences-Guardant rivalry in colorectal testing market heats up

    Exact bolstered its play for the residual disease and recurrence segment by striking a deal to buy Ashion Analytics, while Guardant disclosed availability of its liquid biopsy test for the same market.

    By Feb. 17, 2021
  • Qiagen
    Image attribution tooltip
    Courtesy of Qiagen
    Image attribution tooltip

    Qiagen shuns M&A that 'dilutes' its focus amid reports of Quidel merger

    Qiagen’s CEO said his business development team is focused on bolt-on acquisitions that support and strengthen its operations in five target areas.

    By Feb. 10, 2021
  • Image attribution tooltip
    Permission granted by Quidel Corporation
    Image attribution tooltip

    Report of Quidel-Qiagen tie-up makes 'no sense,' Wall Street analysts say

    Bloomberg reported the two companies are in early discussions. But while one analyst said it was a "plausible, though far-fetched" combination to create a global diagnostics firm, several questioned the wisdom of a union.

    By Feb. 9, 2021
  • Zimmer takes electives hit in Q4, to spin off spine, dental units

    "There's just no doubt that COVID, unfortunately, remains a challenge ... We're seeing the pandemic pressure and the surges continue and, frankly, worsen across pretty much all of our regions and markets," said CEO Bryan Hanson.

    By Feb. 5, 2021
  • PerkinElmer predicts sharp falloff in COVID-19 sales this year

    In a relatively rare admission by a testing company, execs said they expect around 50% of 2021 coronavirus sales to come in the first quarter, beyond which vaccines are tipped to drive down demand.

    By Feb. 3, 2021
  • Image attribution tooltip
    Fotolia
    Image attribution tooltip
    Deep Dive

    3 big predictions for digital health in 2021

    As tech and data sharing become more pervasive, healthcare will likely pivot to being more predictive and telehealth will evolve, giving rise to new modalities of care. This will force companies to invest more in cybersecurity.

    By Rebecca Pifer • Jan. 29, 2021
  • Philips beats Q4 expectations as COVID-19 boosts connected care, slows procedures

    The Dutch conglomerate will continue to be active on the M&A front, CEO Frans van Houten told investors, after striking two deals in the space over the past month worth more than $3.4 billion.

    By Jan. 25, 2021
  • Boston Scientific bets on cardiac wearables with $925M Preventice buy

    The deal is the latest in the fast-growing space, coming on the heels of Hillrom's $375 million BardyDx buy on Tuesday and Philips' $2.8 billion purchase of BioTelemetry last month.

    By Jan. 21, 2021
  • Image attribution tooltip
    Adobe Stock
    Image attribution tooltip

    Haemonetics inks $510M Cardiva takeover to expand hospital business

    The blood products medtech contends the deal will strengthen its portfolio in interventional cardiology and electrophysiology markets.

    By Jan. 21, 2021
  • Image attribution tooltip
    Adobe Stock
    Image attribution tooltip

    Hillrom makes cardiac monitoring play with $375M BardyDx buy

    The deal fits Hillrom's existing heart portfolio and efforts to connect devices to the internet, analysts said, but one raised concerns about Medicare reimbursement.

    By Jan. 20, 2021
  • Thermo Fisher buys Mesa Biotech for $450M to bolster rapid point-of-care testing

    The all-cash acquisition, which includes the potential for an additional $100 million upon completion of milestones, adds Mesa's PCR test platform for SARS-CoV-2, influenza A and B, RSV and strep A to Thermo's portfolio.

    By Jan. 19, 2021
  • Philips to acquire Capsule Technologies in $635M deal, growing patient data capabilities

    The move follows the medtech giant's $2.8 billion acquisition of cardiac monitoring company BioTelemetry in December, one of 2020's largest deals.

    By Jan. 19, 2021
  • A collage showing two nurses, one standing with a mask and another donned in personal protective equipment pulling a curtain shut.
    Image attribution tooltip
    Yujin Kim/MedTech Dive
    Image attribution tooltip

    Pandemic propels health systems to mull insurer acquisitions, partnerships: JPM21

    Advocate Aurora CEO Jim Skogsbergh said "partnering for health plan capability is going to be critical to our success."

    By Samantha Liss • Jan. 14, 2021
  • Steris inks $4.6B buy of Cantel Medical amid flurry of M&A

    It's the biggest deal so far this year. Wall Street analysts said COVID-19 infection concerns should boost Cantel in the long term.

    By Jan. 13, 2021
  • Image attribution tooltip
    Adobe Stock
    Image attribution tooltip

    Healthcare CFOs see fresh wave of M&A in 2021: BDO poll

    Financial distress, a desire to expand into new service lines and efforts to close infrastructure gaps are expected to fuel the upturn, according to the consultants.

    By Jan. 12, 2021
  • Image attribution tooltip
    Fotolia
    Image attribution tooltip

    Medtech M&A to take off after pandemic slowed deals in 2020: EY

    Dealmaking in 2021 will be fueled by financial firepower across the industry at an "all-time high" of nearly $500 billion, according to the consultants.

    By Jan. 10, 2021
  • PerkinElmer inks $591M Oxford Immunotec buy to challenge Qiagen in TB market

    The deal comes amid a flurry of medtech M&A during the first week of 2021. Hologic inked two acquisitions in the women's health space and Stryker said it would buy sensor maker OrthoSensor.

    By Jan. 8, 2021
  • Hologic's $230M Biotheranostics buy its 2nd M&A deal of 2021

    Some Wall Street analysts were surprised by the target, but others suggested the move could strengthen the company for a post-coronavirus environment.

    By Jan. 6, 2021
  • Image attribution tooltip
    Photo courtesy of Stryker
    Image attribution tooltip

    Stryker buys sensor maker in bet on wearables in orthopaedics

    OrthoSensor's technology could complement the medtech's robotics platform and boost its data analytics capabilities, SVB Leerink analysts said in a Tuesday note on the acquisition.

    By Jan. 5, 2021
  • Hologic eyes future post COVID-19 with Somatex Medical tuck-in

    The medical device maker is bulking up its women's health business as molecular diagnostics sales surge due to the pandemic. Wall Street analysts have said these lines are equipped to withstand market uncertainties.

    By Jan. 5, 2021
  • Image attribution tooltip
    Adobe Stock
    Image attribution tooltip

    The top medtech deals of 2020 (and one that got away)

    M&A activity bounced back in the second half of the year, with deals ranging from Teladoc's $18.5 billion Livongo buy to Stryker's drawn-out $4 billion acquisition of Wright Medical.

    By Jan. 4, 2021
  • Image attribution tooltip
    Getty / edited by Healthcare Dive
    Image attribution tooltip

    Hospital giant Tenet goes big on ASCs

    A shift in focus to outpatient settings is also occurring among medical device companies. Both Stryker and Zimmer Biomet have made ASCs more of a priority over the last several years.

    By Samantha Liss • Dec. 22, 2020